Glycyrrhetinic acid, a triterpenoid compound primarily sourced from licorice root, as well as its derivatives produced through structural modification, exhibit noteworthy biological attributes, including anti-inflammatory, anti-tumor, antibacterial, antiviral, and antioxidant effects.
The osteochondral defects (OCDs) resulting from the treatment of giant cell tumors of bone (GCTB) often present two challenges for clinicians: tumor residue leading to local recurrence and non-healing of OCDs. Therefore, this study focuses on developing a double-layer PGPC-PGPH scaffold using shell-core structure nanofibers to achieve "spatiotemporal control" for treating OCDs caused by GCTB. It addresses two key challenges: eliminating tumor residue after local excision and stimulating osteochondral regeneration in non-healing OCD cases. With a shell layer of protoporphyrin IX (PpIX)/gelatin (GT) and inner cores containing chondroitin sulfate (CS)/poly(lactic-co-glycolic acid) (PLGA) or hydroxyapatite (HA)/PLGA, coaxial electrospinning technology was used to create shell-core structured PpIX/GT-CS/PLGA and PpIX/GT-HA/PLGA nanofibers. These nanofibers were shattered into nano-scaled short fibers, and then combined with polyethylene oxide and hyaluronan to formulate distinct 3D printing inks. The upper layer consists of PpIX/GT-CS/PLGA ink, and the lower layer is made from PpIX/GT-HA/PLGA ink, allowing for the creation of a double-layer PGPC-PGPH scaffold using 3D printing technique. After GCTB lesion removal, the PGPC-PGPH scaffold is surgically implanted into the OCDs. The sonosensitizer PpIX in the shell layer undergoes sonodynamic therapy to selectively damage GCTB tissue, effectively eradicating residual tumors. Subsequently, the thermal effect of sonodynamic therapy accelerates the shell degradation and release of CS and HA within the core layer, promoting stem cell differentiation into cartilage and bone tissues at the OCD site in the correct anatomical position. This innovative scaffold provides temporal control for anti-tumor treatment followed by tissue repair and spatial control for precise osteochondral regeneration.
Heterogeneous osteochondral regeneration remains a significant challenge due to the distinct microenvironments across the cartilage, calcified cartilage, and subchondral bone layers. The natural gradient of vascularization from the superficial to deep layers of osteochondral tissue plays a critical role in guiding the differentiation of bone marrow stem cells (BMSCs) into chondrocytes and osteoblasts. In this study, we propose a strategy for gradient heterogeneous osteochondral regeneration using cartilage organoids derived from single BMSCs, leveraging the natural vascularization gradient within osteochondral tissue. We successfully isolated BMSCs from rabbits and generated cartilage organoids via in vitro three-dimensional chondrogenic culture. To mimic the pro-vascular microenvironment, we introduced vascular endothelial growth factor, which promoted the hypertrophic differentiation of the cartilage organoids. We then prepared cartilage organoid/GelMA complexes, with or without the anti-vascular drug Axitinib, and implanted them subcutaneously in nude mice. The vascularized subcutaneous microenvironment induced osteogenic differentiation, while Axitinib treatment created an anti-vascular microenvironment, inhibiting osteogenesis and preserving chondrogenesis within the complexes. Both in vitro and in vivo data demonstrated the crucial role of the vascular microenvironment in regulating osteogenic differentiation of cartilage organoids. Finally, organoid/GelMA cylinders were implanted into a rabbit osteochondral defect, where the gradient vascularization at the defect site guided the organoids to differentiate into both cartilage and bone. This single BMSC-derived cartilage organoid approach enables precise gradient heterogeneous osteochondral regeneration, guided by the natural microenvironment within the osteochondral defect site, representing a significant advancement for clinical applications.